eli lilly zepbound - Search News

News

Lilly to offer highest doses of weight-loss drug Zepbound

Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy. Eli Lilly announced on Monday it will soon make the two highest doses of its popular weight-loss drug Zepbound available for self-paying customers on its website.

Reuters on MSN · 1d

Lilly to offer highest doses of weight-loss drug Zepbound on website

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday.

The Motley Fool on MSN · 3d

Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of its only real competitor in the field, Novo Nordisk.

Lilly to buy gene-editing partner Verve

U.S. News & World Report · 1d

Eli Lilly to Acquire Gene-Editing Therapy Developer Verve Therapeutics for up to $1.3 Billion, Companies Say

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver. (Reporting by Sriparna Roy in Bengaluru;

STAT · 21h

Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.

UPI News on MSN · 17h

Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs.

24mon MSN

Scholar Rock's drug helps patients on Zepbound preserve muscle in trial

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound. Shares ...

16h

Eli Lilly files lawsuits over other companies selling Zepbound and Mounjaro

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...

5don MSN

Down 12%, Should You Buy the Dip on Eli Lilly?

Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...

Lilly’s experimental obesity drug shows promise in early study

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

7don MSN

Lilly Pacts Prohibit Telehealth Sales of Copycat Zepbound

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

5don MSN

Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Becker's Hospital Review6d

Eli Lilly tightens rules for telehealth partners

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results